Fenofibrate in Dyslipidemia and Metformin-Controlled Diabetes
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00349128|
Recruitment Status : Completed
First Posted : July 6, 2006
Last Update Posted : September 3, 2007
|Condition or disease||Intervention/treatment||Phase|
|Dyslipidemia/Glucose Metabolism Disorder||Drug: fenofibrate and metformin combination (drug)||Phase 2 Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||382 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||A Randomized, Double-Blind Trial Assessing the Efficacy and Safety of Low and Standard Doses of Fenofibrate in Combination With Metformin on the Lipid Profile in Patients With Type 2 Diabetes and Dyslipidemia.|
|Study Start Date :||January 2004|
- Change in fasting triglycerides.
- Assessment of lipid and glucose metabolisms.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00349128
|Study Director:||Global Clinical Director Solvay||Solvay Pharmaceuticals|